In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates.

@article{Davis2012InVC,
  title={In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates.},
  author={John A. Davis and Dan A. Rock and Larry C. Wienkers and Josh T. Pearson},
  journal={Drug metabolism and disposition: the biological fate of chemicals},
  year={2012},
  volume={40 10},
  pages={
          1927-34
        }
}
The in vitro characterization of the inhibition potential of four representative maytansinoid species observed upon hepatic and/or tumor in vivo processing of antibody-maytansine conjugates (AMCs) with cleavable and noncleavable linkers is reported. We investigated the free maytansinoid species N(2')-deacetyl-N(2')-(3-mercapto-1-oxopropyl)-maytansine (DM1), (S)-methyl-DM1, and N(2')-deacetyl-N(2')-(4-mercapto-4-methyl-1-oxopentyl)-maytansine (DM4) as representative cleavable linker catabolites… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates.

  • Drug metabolism and disposition: the biological fate of chemicals
  • 2014
VIEW 7 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

New Insights in Tissue Distribution, Metabolism, and Excretion of [3H]-Labeled Antibody Maytansinoid Conjugates in Female Tumor-Bearing Nude Rats.

  • Drug metabolism and disposition: the biological fate of chemicals
  • 2016
VIEW 2 EXCERPTS
CITES METHODS & BACKGROUND

"Target-Site" Drug Metabolism and Transport.

  • Drug metabolism and disposition: the biological fate of chemicals
  • 2015
VIEW 1 EXCERPT
CITES METHODS

References

Publications referenced by this paper.
SHOWING 1-10 OF 29 REFERENCES

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)positive breast cancer after prior HER2-directed therapy

HA 3rdBurris, HS Rugo, +7 authors S Girish
  • J Clin Oncol 29:398–405
  • 2011